Compare Lowe`s Companies Inc (LOW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Lowe`s Companies Inc trades at $191.01 (market cap $105.89B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Lowe`s Companies Inc is far larger — about 14.1× Spyre Therapeutics Inc. Common Stock's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LOW | SYRE | |
|---|---|---|
Market Cap | $105.89B | $7.52B |
Volume | 3,104,115 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $108.92 |
52-Week Low | $179.50 | $22.18 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.74B | $6.52B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.77, up 1.72% with recent earnings beats but faces bearish technical signals. The stock shows solid fundamentals with a P/E of 15.95 and net margin of 7.35%, though revenue declined to $83.67B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while analyst consensus remains strongly bullish with a $244.09 price target representing 29% upside potential.
LOW presents a value opportunity with attractive valuation metrics and consistent dividend payments, but faces headwinds from slowing home improvement demand and elevated debt levels. The stock's negative shareholder equity and competitive pressure from Home Depot require careful monitoring, though institutional support remains strong with 60.79% buy ratings.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
